Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.
about
Clinical perspectives on echinocandin resistance among Candida speciesEchinocandin resistance: an emerging clinical problem?Regional data analysis of Candida non-albicans strains collected in United States medical sites over a 6-year period, 2006-2011.Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates.Positions and numbers of FKS mutations in Candida albicans selectively influence in vitro and in vivo susceptibilities to echinocandin treatment.Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance.Posttreatment Antifungal Resistance among Colonizing Candida Isolates in Candidemia Patients: Results from a Systematic Multicenter Study.Echinocandin Resistance in Candida.Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream InfectionOptimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrationsBiofilm Production and Antibiofilm Activity of Echinocandins and Liposomal Amphotericin B in Echinocandin-Resistant Yeast Species.Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geogrEchinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.Mechanisms of Antifungal Drug Resistance.Mechanisms of echinocandin antifungal drug resistance.Epidemiology and antifungal susceptibilities of yeast isolates causing invasive infections across urban Beijing, China.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials.Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality.Echinocandin Resistance in Candida Species: a Review of Recent Developments.In Vitro Interactions of Echinocandins with Triazoles Against Multidrug-Resistant Candida auris.Frequency of the Paradoxical Effect Measured Using the EUCAST Procedure with Micafungin, Anidulafungin, and Caspofungin against Candida Species Isolates Causing Candidemia.Paradoxical antifungal activity and structural observations in biofilms formed by echinocandin-resistant Candida albicans clinical isolates.Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment.Culture-Independent Molecular Methods for Detection of Antifungal Resistance Mechanisms and Fungal Identification.The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp.In Vitro Exposure to Increasing Micafungin Concentrations Easily Promotes Echinocandin Resistance in Candida glabrata Isolates.Identification of Genes in Candida glabrata Conferring Altered Responses to Caspofungin, a Cell Wall Synthesis Inhibitor.Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance.Echinocandin failure case due to a previously unreported FKS1 mutation in Candida krusei.In vitro antifungal susceptibility of Candida glabrata to caspofungin and the presence of FKS mutations correlate with treatment response in an immunocompromised murine model of invasive infectionAntifungal resistance: current trends and future strategies to combat.Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates.Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria.Evaluation of caspofungin susceptibility testing by the new Vitek 2 AST-YS06 yeast card using a unique collection of FKS wild-type and hot spot mutant isolates, including the five most common candida species.Use of anidulafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4,290 clinical isolates of Candida by using CLSI methods and interpretive criteria.EUCAST technical note on Candida and micafungin, anidulafungin and fluconazole.Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata.Candida glabrata Biofilms: How Far Have We Come?
P2860
Q28082538-780F544E-845D-4F80-8043-7DF2DE34B852Q28544739-3D46E22D-90A5-42A3-AF91-83F48D52F5E9Q30826889-AD1E1C99-E060-446D-907C-B3A1F953764AQ33622743-08CA9136-2007-45DB-87D9-05ED42CFE449Q33798606-C74E2FF4-77BA-4C53-A2F2-591C8B1E047AQ34058099-8130231B-0EA7-49CD-A903-06BC34DC12E1Q35880078-0BBB7655-84D8-4F7A-AE1F-28621A1DAA5FQ36276186-0ED2B3DF-E684-4D92-87E7-622C45A2002DQ36290758-6B258B77-70E7-48E3-8DA7-262A5A9542D9Q36364100-94BF244A-037F-4296-87FB-4DFA90DFAD56Q36856930-3B539DDB-B05C-478E-9FB6-A1A49866DC30Q36933366-FA70BDD4-EE5C-4DF2-A1A9-7DB3BED2DDCBQ37036246-265FD1A0-B91B-4FAF-90DF-01D845AF9999Q38254290-91BD2EF6-2B3F-4177-ADF7-71F8AA267C57Q38266675-30CA29EA-14A1-470C-92BC-3C374B4BE915Q38550402-0B323753-EFD9-442E-9166-10FB5F731890Q38610744-FC88F102-5429-4CC3-A882-8E44D4444FFAQ38681635-2AA5295D-FF65-4CE1-BEAF-CB9288662624Q38811035-2B685E84-0399-4632-992B-91CB14A9B0D2Q38919690-5FB2D583-1125-431C-97E0-1E7B60BA70FFQ38988521-693D01E5-1868-444F-9BA0-120034210808Q39092177-224DE775-F544-40A7-88A6-5DF8828086F6Q39230127-1C3C967A-63C8-4125-BE71-243109C08058Q39977764-2DCF467C-981B-44E0-87AD-20219549460EQ40040802-C8A99C17-8919-4470-8B73-BBB1FD2A9CD7Q40045673-81A96E00-2D2A-4ECF-B7EF-043BE45A7722Q40340923-3AA167E3-ED1C-4932-A8FE-3A661B10B63CQ40441738-A9D93DFE-040D-4953-BA61-0FC588647EDCQ40602821-04B7E60F-FE72-40BA-A193-DA44CCD61378Q40738359-18E962C1-CA8F-4A3D-8609-668F3069270DQ41075366-ABC89880-81A2-4F72-BF53-7FE2763D2CEEQ41079741-CF9234EB-CCEF-4198-86E0-ED787ECA1BB3Q41632930-8CCB6598-8D8D-4B8B-AAE5-2D6665960550Q41907460-65369C1D-A2D8-457E-9A39-4770CD9D7ED8Q41908678-E6FFF0B1-9D63-4CE3-A184-CA9EBF516E57Q42529877-F624BAB1-DBF1-401D-88B9-E50ECAB3E87FQ43125888-C0CA3685-E82C-409F-924B-5237252670EEQ44013179-7EE326A2-D644-43D8-97C7-CC1A2A437CE8Q47410811-7B8D492A-AD20-43F5-9A86-9277ED5A390AQ48163274-356240DA-A7BC-4C07-AEF0-F9B5C2AD22FF
P2860
Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Differential in vivo activitie ...... hout FKS resistance mutations.
@ast
Differential in vivo activitie ...... hout FKS resistance mutations.
@en
type
label
Differential in vivo activitie ...... hout FKS resistance mutations.
@ast
Differential in vivo activitie ...... hout FKS resistance mutations.
@en
prefLabel
Differential in vivo activitie ...... hout FKS resistance mutations.
@ast
Differential in vivo activitie ...... hout FKS resistance mutations.
@en
P2093
P2860
P356
P1476
Differential in vivo activitie ...... hout FKS resistance mutations.
@en
P2093
David S Perlin
Joanne Goodwin
Maiken Cavling Arendrup
Susan Julie Howard
P2860
P304
P356
10.1128/AAC.06369-11
P407
P577
2012-02-21T00:00:00Z